The FDA has approved AstraZeneca's treatment for use outside of healthcare facilities, but it will still require a prescription.
On Friday, the FDA approved the at-home use of FluMist, allowing those who are hesitant about needles to access a potentially lifesaving nasal spray flu vaccine more easily.
This marks the first time parents can administer the vaccine to children, and adults can use it themselves outside of a healthcare facility, although a prescription will still be necessary. FluMist is expected to be available from online pharmacies by next fall.
AstraZeneca, the producer, plans to launch a FluMist Home website where users can complete a questionnaire reviewed by a pharmacist before the treatment is shipped directly to them. The nasal spray will also remain available for in-office use. The current cost for a dose is approximately $35 to $45, depending on insurance coverage.
Dr. Peter Marks, director of the FDA’s vaccine center, emphasized that this approval offers a convenient option for families to receive a safe and effective flu vaccine. The FDA required AstraZeneca to demonstrate that the instructions for at-home use were clear and feasible, concluding that they were, but recommending that caregivers administer the spray to children aged 2 to 17.
Dr. Abraar Karan, an infectious disease specialist, noted that logistical barriers often prevent people from getting vaccinated, including the need for appointments and recovery time. He believes that the new at-home option will reduce these barriers and encourage more people to get vaccinated before flu season begins.
Read next
23:20
U.S. Defense Secretary Pete Hegseth told Indo-Pacific allies Saturday they won’t be left alone against growing military and economic pressure from China—but they must also boost their own defense efforts.
22:43
Iran said on Saturday that it has officially received a new nuclear deal proposal from U.S. President Donald Trump, delivered by Oman during a diplomatic visit to Tehran.
19:55
US
The US Supreme Court has ruled that the Trump administration can temporarily end legal protections for more than 500000 migrants from Cuba, Haiti, Nicaragua, and Venezuela, exposing them to possible deportation.
16:30
US tariffs
The European Commission voiced strong regret over the United States’ decision to raise tariffs on imported steel to 50%, warning the move adds uncertainty to the global economy.
11:56
vaccine
The U.S. FDA has approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for adults aged 65 and older and those aged 12–64 with risk factors, marking a major step under tighter regulations.
What is your opinion on this topic?
Leave the first comment